Maze Therapeutics has set out plans for a $131 million IPO as the company prepares to start dosing its lead kidney drug in a phase 2 trial. The Bay Area-based biotech unveiled its ambition earlier ...

Obesity biotech Metsera and renal and metabolic-focused Maze Therapeutics have met their IPO expectations as the two companies prepare to join the Nasdaq this morning. While Metsera is offering ...

Maze seeks as much as $133 mln in New York IPO Backers include Alphabet's GV and Third Rock Ventures Biotech IPOs set for ramp up in coming weeks Jan 27 (Reuters) - Drug developer Maze ...

follies and surprises' and has been a massive hit with kids and big kids (aka their parents!) since it opened in nearly 30 years ago now in 1997. The future of the attraction was threatened just a ...

Most smartwatches designed for kids let you text, call and use GPS tracking. To find the best smartwatches for kids, we tested more than a dozen with kids of varying ages in elementary and middle ...

Jonathan Orszag, the co-founder of economic consulting firm Compass Lexecon, is making a fresh bet that mergers and acquisitions are only going to get more complicated. Orszag and eight other ...

Teaching your kids about financial responsibility at a young age helps build strong financial literacy that will benefit them throughout life. The earlier you start, the better positioned they ...

“We have terrific youth mental health service providers in the state, but we don’t have a system for kids, and so it ends ... Like an impenetrable maze, families hit dead end after dead ...